# Questions to ask at a first GLP-1 treatment discussion

Clarify the medication, formulation, medical rationale and follow-up before comparing GLP-1 offers.

Canonical: https://velri.co/blog/compounded-vs-brand-glp1-plus-size-mom-first-script-questions
Publisher: Velri (https://velri.co/about)
Published: 2026-06-19
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A first GLP-1 treatment discussion should clarify the exact medication being considered, why it may fit the person's health history and how the proposed product will be supplied.

For compounded semaglutide or tirzepatide, there is an additional question: what individual medical need supports using a compounded preparation? FDA says compounded drugs should be used only when an approved drug cannot meet the patient's medical needs. [1][2]

## Identify the finished preparation

Ask for the active ingredient, formulation and route. If another ingredient is included, its identity and reason for inclusion should be explained too.

Compounded medications are not FDA-approved. FDA does not review their safety, effectiveness or quality before marketing, and a compounded drug is not an FDA-approved generic. [1]

## Understand the medical reason

The discussion should connect the proposed treatment to the person's health history, other medicines and the risks relevant to that person. A website's general description cannot complete that assessment.

For routine copies of available drugs, federal compounding restrictions also matter. FDA's April 2026 clarification explains the role of a documented, patient-specific significant difference under 503A. A change such as adding another ingredient does not automatically satisfy that condition. [3]

The explanation should identify the difference that matters for this particular prescription.

## Know who handles the follow-up

The prescriber should explain how questions and new symptoms are reviewed. The dispensing pharmacy should be identifiable and reachable for questions about the preparation, label and handling.

FDA has documented problems involving compounded GLP-1 products, including unclear dosing, measurement errors, fraudulent labeling and inadequate refrigeration during shipping. These findings make product-specific instructions and follow-up important. [2]

Before the conversation ends, it should be clear where to ask a medical question, where to ask a pharmacy question and what information will accompany the order.

## Sources
[1] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[2] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[3] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support